Downregulation of KAT2B has been reported in several cancers and is associated with poor prognosis, including hepatocellular carcinoma, esophageal squamous cell carcinomas, lung adenocarcinoma, gastric cancer, colorectal cancer and cervical carcinoma [39–44]. Here, KAT2B is linked to lung adenocarcinoma.